ARTICLE | Company News
PanOptica, Astellas deal
January 10, 2011 8:00 AM UTC
Astellas' OSI Pharmaceuticals Inc. subsidiary granted PanOptica exclusive, worldwide rights to develop and commercialize PAN-90806 for ophthalmic indications. The small molecule selective inhibitor ...